TNBC By Rejiv Rajendranath
Session 5: TNBC
Chairpersons :
S H Advani, S Hukku
Speaker :
Rejiv Rajendranath
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR triple negative breast cancer (TNBC)
Author: T. A. Traina
Conference:ASCO
Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), anandrogen receptor (AR) signaling inhibitor, in AR+ advanced triple negative breast cancer (aTNBC)
Author: J. Cortes
Conference: ESMO
Phase III trial of etirinotecan pegol (EP) versus treatment of physician’s choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine : The BEACON Study
Author: E.A. Perez
Conference: ASCO